BioSpace News Archive

*Core revenue is a non-GAAP financial measure. A reconciliation of core revenue to GAAP revenue is included under the heading “Non-GAAP Financial Measures” below..

Baudax Bio, Inc. announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 182,187 shares of Baudax Bio’s common stock and restricted stock units covering 56,384 shares of Baudax Bio’s common stock to 17 newly-hired employees, with a grant date of March 31, 2020.

To provide global vision and opportunities for the intelligent coordination between pharmaceutical enterprises and logistics service and equipment suppliers, P-Logi China 2020, organized by Informa Markets and CCCMHPIE and co-organized by Sinoexpo Informa Markets

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quintás Cardama, M.D., Chief Medical Officer of TCR 2 Therapeutics, will present an update on company progress during the panel “Emergence of TCRs and Next-Generation Therapies” at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, has learnt that buy recommendations and letters are being circulated in Germany. The Company, along with the Federal Financial Supervisory Authority of Germany (“BaFin”) suggests shareholders fully understand these materials. BaFin advises all investors to check the information given in the buy recommendations by consulting sources, especially if the buy recom

Cigna and Express Scripts are working with Buoy Health to provide an early intervention screening tool to help customers and members understand their personal risks for COVID-19. The digital tool immediately triages symptoms and recommends next steps for care, while also relieving demand on an over-burdened health

Systimmune Inc, a clinical-stage biopharmaceutical company developing multi-specific antibody therapies in oncology, today announces manufacturing development and production of a SARS-CoV-2 neutralizing protein SI-F019 at levels ready for preclinical testing.

Global Blood Therapeutics, Inc. announced that on April 1, 2020, the compensation committee of GBT’s board of directors granted three new employees restricted stock units for an aggregate of 10,550 shares of the company’s common stock.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that it will present safety and efficacy data from its two vafidemstat clinical trials in Alzheimer’s disease (AD), REIMAGINE-AD and ETHERAL, at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD 2020 meeting, to be held April 2-5, 2020.

resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administered, small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), alone or in combination with sirolimus, in Parkinson’s disease (PD).